GHK-Cu dosing, what studies used rather than what to take
By The PepVise Editorial Team · Reviewed August 6, 2026 · 8 min read
GHK-Cu dosage on the evidence: the topical concentrations used in skin and hair studies, why injectable dosing has no human trial behind it, and why the literature reports amounts rather than prescribing them.
Mechanism explainers on PepVise aim for textbook-level clarity without the textbook's refusal to commit to a reading.
What readers ask us next.
- What is the standard GHK-Cu dose?
- There is no standard clinical dose, because GHK-Cu is not an approved therapeutic and no guideline sets one. Topical cosmetic products use low percentage concentrations, while injectable amounts shared online are seller conventions with no controlled human study behind them.
- What concentration of GHK-Cu is used in skin products?
- Formulation and cosmetic literature discusses GHK-Cu at low percentage concentrations in serums and creams, with work such as Badenhorst 2016 examining its stability as a formulated ingredient. This describes cosmetic use, not a validated therapeutic dose.
- Is there a safe injectable GHK-Cu dose?
- No injectable dose has been established in a controlled human trial. Beyond the general lack of evidence, injecting a copper-containing peptide raises specific safety concerns because copper balance is tightly regulated and excess copper is toxic, so cited amounts are conventions rather than validated safe doses.
- Why do sources avoid giving a GHK-Cu dose to take?
- Because responsible reporting distinguishes describing what studies used from prescribing what a reader should take. With no approved indication and no clinical guideline, stating a dose to take would imply an evidence base that does not exist for this compound.
References cited on this page.
PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.
- [01]Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci 2018
- [02]Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization and stability of the copper-binding tripeptide GHK-Cu. Pharm Dev Technol 2016
- [03]Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007
About The Pepvise Editorial Team
The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.
Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →
Adjacent in the literature.
BPC-157, What the Evidence Shows
Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.
16 min readCompounds · Compound profileTB-500, The Field Guide
TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.
14 min readCompounds · Compound profileGHK-Cu, Evidence and Hype
Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.
13 min readGet the 2026 Peptide Evidence Ledger.
A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.
By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.